Sentences with phrase «in products liability litigation»

Aging impacts tires dramatically, without regard to miles driven, and the firm continues to address this important safety issue in products liability litigation.

Our defective drywall lawyers are leaders in products liability litigation.

G. Owen, Punitive Damages in Products Liability Litigation, 74 Mich..

His experience in products liability litigation encompasses mass torts involving latex gloves, cough and cold medications, antibiotics, food flavorings, hypertension medications and anti-coagulants.

Although every case is unique, there should rarely, if ever, be a situation in products liability litigation where a plaintiff is able to keep his own conduct from the fact finder through a tactical maneuver.

When you choose our Actos lawyer, you choose representation by some of the top attorneys in the country who have a proven record of success in products liability litigation.

It came in products liability litigation against Pfizer Inc. related to its erectile dysfunction drug Viagra.

Tomorrow, I will moderate an Above the Law webcast that will discuss emerging trends in products liability litigation and provide an introduction to Lex Machina's products liability analytics.

Our firm is respected as a leader in products liability litigation and has a solid history of successfully representing plaintiffs in pharmaceutical litigation.

The firm was also recognized for its strength in Product Liability Litigation by The BTI Consulting Group.

Represented multinational pharmaceutical company in product liability litigation in courts across the country and before the Judicial Panel on Multidistrict Litigation.

I started in the legal industry as a Database / Litigation Analyst for a large international firm in the Midwest that specialized in product liability litigation.

David Marshall specializes in representing defendants in product liability litigation, including toxic torts, and long - term care facilities, assisted living facilities and related specialties.

Representative examples of experience in product liability litigation include:

Victory for pharmaceutical giants Pfizer in a product liability litigation about alleged cardiovascular injuries associated with testosterone replacement therapies

Expert development and MDL coordinating counsel for global pharmaceutical company in product liability litigation involving medication to treat gastrointestinal conditions

He also defends clients in product liability litigation, particularly matters involving pharmaceutical products and energy, especially claims relating to fuel gases.

Our years of litigation experience, combined with our dedication and resources, have made us a leader in product liability litigation.

Our Dallas and Houston defective drug lawyers represents clients in product liability litigation throughout the United States, and we employ an expansive bank of resources to develop solid strategies that our clients may rely upon.

In September 2014, the firm was recognized by the BTI Consulting Group as a «Standout» in Complex Commercial Litigation and Employment Litigation, ranking among the top 22 and top 18 law firms in the country, respectively, and for its strength in Product Liability Litigation and Securities and Finance Litigation.

Chapter 11: «Emerging Issues in Medical Device Litigation,» in PRODUCT LIABILITY LITIGATION: CURRENT LAW, STRATEGIES AND BEST PRACTICES (Practising Law Institute)(2012)

Won dismissal for American Regent / Luitpold Pharmaceuticals in product liability litigation involving allegedly defective pharmaceutical products.

Demonstratives can frequently be used very effectively in product liability litigation, in which the issue is whether a product was manufactured negligently, causing harm — or in some cases, whether a product that was manufactured and used properly still caused harm to a consumer that leads to liability on the part of the manufacturer or seller.

Serve as national coordinating and trial counsel in product liability litigation for manufacturers of consumer and commercial products.

Our years of experience in product liability litigation, combined with our dedication and resources, have made us a leader in our field.

It may well be that the coming (and to some extent existing) revolution in genetically individualized medical therapy will require changes in how drugs are evaluated, labeled, etc., but this is a singularity - driven issue that needs to be addressed by the policy branches of our government, and not haphazardly in product liability litigation.

Defended aircraft manufacturer in product liability litigation in state and federal courts arising from fatal crashes in general aviation.

Carlton Fields has represented major manufacturing companies in product liability litigation in state and federal courts nationwide for more than 30 years.

For more than 25 years, John has defended manufacturers in product liability litigation in trial and appellate courts involving a multitude of products ranging from ATVs and RVs to suction vibrasorbers.

Except for a brief, misguided trip to the «dark side,» Rachel has spent her whole career defending drug and device manufacturers in product liability litigation and in government actions arising from such litigation.

He has substantial experience in product liability litigation as well, having handled lawsuits involving a variety of products, including airplanes, helicopters, turbine and piston aircraft engines, grade - crossing warning systems, racquetball safety eyewear, farm equipment, multipiece truck wheels, automobile tires, chainsaws, playground equipment, and rigging equipment for stunt and sailing applications.

Kevin is a trial attorney concentrating his practice in product liability litigation and mass tort, defending corporations and individuals in personal injury claims involving automobiles and other consumer products.

Thus, the application of the First Amendment to FDA administrative actions was not analogous to preemption in product liability litigation:

At Field Law, our Litigation Practice Group has extensive experience representing manufacturers, distributors, installers and related entities involved in product liability litigation.

The Bryan Cave Product Liability team has substantial experience representing companies from a wide array of industries in product liability litigation involving wrongful death, personal injury and commercial disputes.

I serve as national coordinating counsel and local counsel for large corporations in product liability litigation, developing and coordinating global defence strategies.

In product liability litigation, we represent pharmaceutical and medical device makers and distributors in all aspects of national and international litigation as: (a) lead trial counsel, (b) national or global coordinating counsel, (c) resolution counsel, and (d) appellate counsel.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry ® World ™; risks related to the collection, storage, transmission, use and disclosure of confidential and personal information; BlackBerry's ability to manage inventory and asset risk; BlackBerry's reliance on suppliers of functional components for its products and risks relating to its supply chain; BlackBerry's ability to obtain rights to use software or components supplied by third parties; BlackBerry's ability to successfully maintain and enhance its brand; risks related to government regulations, including regulations relating to encryption technology; BlackBerry's ability to continue to adapt to recent board and management changes and headcount reductions; reliance on strategic alliances with third - party network infrastructure developers, software platform vendors and service platform vendors; BlackBerry's reliance on third - party manufacturers; potential defects and vulnerabilities in BlackBerry's products; risks related to litigation, including litigation claims arising from BlackBerry's practice of providing forward - looking guidance; potential charges relating to the impairment of intangible assets recorded on BlackBerry's balance sheet; risks as a result of actions of activist shareholders; government regulation of wireless spectrum and radio frequencies; risks related to economic and geopolitical conditions; risks associated with acquisitions; foreign exchange risks; and difficulties in forecasting BlackBerry's financial results given the rapid technological changes, evolving industry standards, intense competition and short product life cycles that characterize the wireless communications industry.

Important factors that could cause actual results to differ materially from those expressed or implied by such forward - looking statements include, without limitation, possible product defects and product liability, risks related to international sales and potential foreign currency exchange fluctuations, the initiation or outcome of litigation, acts or potential acts of terrorism, international conflicts, significant fluctuations of quarterly operating results, changes in Canadian and foreign laws and regulations, continued acceptance of RIM's products, increased levels of competition, technological changes and the successful development of new products, dependence on third - party networks to provide services, dependence on intellectual property rights, and other risks and factors detailed from time to time in RIM's periodic reports filed with the United States Securities and Exchange Commission, and other regulatory authorities.

He works in law firm Wiggin & Dana's litigation department with a practice focused on product liability and aviation litigation, amusement / leisure counseling and litigation, and general business litigation.

Paul Maloney is a trial lawyer who focuses his practice in product liability, professional liability, and commercial litigation.

Mr. Leopold specializes in consumer justice litigation with a focus on complex products liability, managed care, catastrophic injury and class action litigation.

Brandon concentrates his practice in general civil litigation matters; including premises liability, product liability, construction and various insurance defense cases.

Among his other distinctions, Stewart has been recognized by The Best Lawyers in America for the areas of Medical Malpractice Law (2013 — present), Personal Injury Litigation (2014 — present) and Product Liability Litigation (2016 — present).

He was recently named a 2018 Best Lawyers in America «Lawyer of the Year» in the practice area of Product Liability Litigation — Plaintiffs in West Palm Beach for his expertise.

The L.A. office opens with strong capabilities in areas including cyber risk, sports and entertainment, and complex product liability litigation, and will expand to cover the firm's full set of capabilities spanning all areas of civil litigation, corporate transactions, regulatory compliance, and risk - avoidance counsel.

John has served as an expert witness regarding issues in asbestos litigation; he is a frequent speaker and commentator on products liability litigation; and he has coordinated clients» lobbying efforts in the U.S. House and Senate to create national asbestos legislation.

Stephen has a broad civil litigation practice with extensive experience in breach of trust claims, commercial disputes, construction liens, construction and environmental liability claims, First Nations consultation rights in land development, insurance coverage, product liability, professional liability and subrogation.